Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shoei Yakuhin Co., Ltd. ( (JP:3537) ) has issued an announcement.
Shoei Yakuhin reported consolidated net sales of ¥20.28 billion for the quarter ended December 2025, a 7.4% increase from the previous year, while operating profit declined 21.3% to ¥391 million and ordinary profit fell 13.7% to ¥550 million, reflecting rising costs or margin pressure despite revenue growth. Profit attributable to owners of the parent decreased 16.5% to ¥365 million, basic earnings per share slipped to ¥106.86, and the capital adequacy ratio weakened from 52.3% to 48.2% even as total assets and net assets rose, indicating a more leveraged but expanding balance sheet, with no interim dividend paid for the second quarter.
The most recent analyst rating on (JP:3537) stock is a Hold with a Yen1644.00 price target. To see the full list of analyst forecasts on Shoei Yakuhin Co., Ltd. stock, see the JP:3537 Stock Forecast page.
More about Shoei Yakuhin Co., Ltd.
Shoei Yakuhin Co., Ltd. is a Japan-based company listed on the Tokyo Stock Exchange Standard market, operating in the general business category. The company is involved in the pharmaceutical and related healthcare products field, focusing on domestic sales and distribution within Japan’s medical and consumer markets.
Average Trading Volume: 3,903
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen5.48B
Find detailed analytics on 3537 stock on TipRanks’ Stock Analysis page.